Tech Company Financing Transactions

Karuna Therapeutics Funding Round

Arch Venture Partners, private investors and PureTech Ventures invested in a $42 million Series A venture round for Karuna Therapeutics. This venture round was announced on 8/3/2018.

Transaction Overview

Company Name
Karuna Therapeutics
Announced On
8/3/2018
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series A
Investors

Arch Venture Partners (Robert Nelsen)

private investors (Steven Paul)

PureTech Ventures

The Wellcome Trust

Proceeds Purpose
Karuna plans to use the proceeds from the financing to advance its lead product candidate, KarXT (Karuna-xanomeline-trospium chloride), including the initiation of a Phase 2 trial in patients with schizophrenia in the third quarter of 2018 and the expansion into other therapeutic areas, including a non-opiate pain indication.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
33 Arch St. 3110
Boston, MA 02110
USA
Phone
(617) 482-3337
Website
www.karunatx.com
Email Address
[email protected]
Overview
Karuna Therapeutics (Nasdaq: KRTX) is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
Profile
Karuna Therapeutics LinkedIn Company Profile
Social Media
Karuna Therapeutics Company Twitter Account
Company News
Karuna Therapeutics News
Facebook
Karuna Therapeutics on Facebook
YouTube
Karuna Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Steven Paul
  Steven Paul LinkedIn Profile  Steven Paul Twitter Account  Steven Paul News  Steven Paul on Facebook
Chief Financial Officer
Troy Ignelzi
  Troy Ignelzi LinkedIn Profile  Troy Ignelzi Twitter Account  Troy Ignelzi News  Troy Ignelzi on Facebook
Chief Medical Officer
Stephen Brannan
  Stephen Brannan LinkedIn Profile  Stephen Brannan Twitter Account  Stephen Brannan News  Stephen Brannan on Facebook
Chief Operating Officer
Andrew Miller
  Andrew Miller LinkedIn Profile  Andrew Miller Twitter Account  Andrew Miller News  Andrew Miller on Facebook
Vice President
Giorgio Attardo
  Giorgio Attardo LinkedIn Profile  Giorgio Attardo Twitter Account  Giorgio Attardo News  Giorgio Attardo on Facebook
VP - Finance
Jason Brown
  Jason Brown LinkedIn Profile  Jason Brown Twitter Account  Jason Brown News  Jason Brown on Facebook
VP - R & D
Christian Felder
  Christian Felder LinkedIn Profile  Christian Felder Twitter Account  Christian Felder News  Christian Felder on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/3/2018: HYAS Infosec venture capital transaction
Next: 8/3/2018: Willow venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on tech company VC transactions. All VC database entries reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.